

For further information, contact:

Dr. Robert B. Harris

President/CEO, CBI

Phone: 800 735 9224

Fax: 804 648 2641

Delayed Contract Work to Begin at Commonwealth Biotechnologies, Inc.

Work delayed Since 3Q 2004 to begin in May, 2005

RICHMOND, VA (April 28, 2005) - Commonwealth Biotechnologies, Inc. (NASDAQ SmallCap Market: CBTE), today announced that work pertaining to assay of human clinical trial samples will get underway in May. This particular contract was awarded to CBI in July, 2004 and all run-up work in anticipation of receipt of the clinical trial samples in September, 2004 was completed by August, 2004. However, the entire clinical trial program was delayed while the sponsor dealt with regulatory issues. These issues have now been resolved, and the first samples are expected at CBI in May.

The assay work for the clinical trial represents a significant revenue stream for CBI, totaling nearly \$ 900,000 over a 9 month period. Almost 8 months has elapsed since the original anticipated start date for the clinical trial and CBI's anticipated revenues from these analyses (about \$730,000) has also been delayed for the same time.

"We are very excited that the analytical work for this clinical trial can finally get underway," explained Robert B. Harris, President and CEO, CBI. "Lack of revenues from this contract have negatively impacted CBI's anticipated top and bottom line performance for the past 3 quarters, but now we look forward to making up lost ground."

#

About CBI

Commonwealth Biotechnologies, Inc. is a comprehensive provider of contract research and development services to the global biotechnology industry, academic institutions, government

agencies, and pharmaceutical companies. It offers cutting-edge expertise and a complete array of the most current analytical and synthetic chemistries and biophysical analysis technologies, many of which are not available from other commercial sources. Services include DNA analyses, genomics, proteomics, biochemical analyses, mass spectral analysis, microbiological services, pathogen testing, food microbiology, peptide services, protein sequencing and drug discovery, and through its FIL division, CBI offers comprehensive genetic identity testing, including paternity, forensic, and CODIS analyses. CBI is accredited by the American Association of Blood Banks, CLIA, and the National Forensic Science Technology Council, and operates fully accredited BSL-3 laboratory. For more information, visit CBI on the web at www.cbi-biotech.com and visit FIL at www.fairfaxidlab.com.

#

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in the Company's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. No statement herein should be considered an offer of any securities. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as the date hereof. Specifically, there can be no guarantee that: (a) CBI will receive all fees anticipated under the contract referenced herein; or (b) CBI's customers will not terminate such contract prior to their completion. A number of factors, including customer demand, industry trends, armed conflict, and terrorist activities could alter these trends referenced herein. CBI undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.